A Kangmei Pharmaceutical booth at a trade and services fair in Beijing. The company has been under investigation since December for breach of disclosure rules. Photo: Reuters
Chinese MSCI constituent firm Kangmei Pharmaceutical faces 600,000 yuan fine for misstating cash position by 29.9bn yuan
- Company used fraudulent bank documents to inflate its cash deposits and falsified business certificates to inflate its income between 2016 and 2018, CSRC says
Follow your favourite topic and get notified
A Kangmei Pharmaceutical booth at a trade and services fair in Beijing. The company has been under investigation since December for breach of disclosure rules. Photo: Reuters